A new study published in Nature Genetics identified more than 160 genetic associations for restless leg syndrome. The genetic findings also point researchers to possible drug targets for treating the condition. Curious how restless leg syndrome might impact your health? Learn more on our blog: https://23and.me/3VSILUu
About us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
- Website
-
https://www.23andme.com
External link for 23andMe
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Sunnyvale, California
- Type
- Public Company
- Specialties
- genetic research, consumer genetics, direct-to-consumer genetic testing, telehealth, healthcare, wellness, therapeutics, and drug discovery
Locations
-
Primary
223 N Mathilda Ave
Sunnyvale, California 94086, US
-
349 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at 23andMe
Updates
-
Great panel today at Aspen Ideas discussing how genetic data is transforming cancer and other diseases with Anne Wojcicki and other #WomenInSTEM! 🧬
-
-
We’re looking for a Social Expert & Content Creator to join our brand team! This is a Senior Manager position that will build and create content for 23andMe and Lemonaid Health social media channels. https://lnkd.in/grvi4tcW
Social Expert & Content Creator (Senior Manager) – 23andMe Careers
23andme.com
-
Did you hear about the new genetic study of sacrifice victims from the Maya city of Chichén Itzá that was published last week? In it, a team of researchers from Germany and Mexico discovered that contrary to the popular assumption that the Maya primarily sacrificed young women and girls, all of the sacrifice victims from this ancient site were young boys, and many of them were related. Read the genetic study here: https://lnkd.in/gBkAZjMv Now thanks to our new Historical Matches℠ feature, you can find out if you are distantly related to any of the young boys who were sacrificed at Chichén Itzá or hundreds of other historical individuals. Learn more on our blog: https://23and.me/3KPyO3Y
-
-
A new genome-wide association study of coffee intake in US-based 23andMe participants explores the relationships of coffee intake with multiple biomarkers, health characteristics, and lifestyle traits. https://lnkd.in/gvf4Nfig
Genome-wide association studies of coffee intake in UK/US participants of European ancestry uncover cohort-specific genetic associations - Neuropsychopharmacology
nature.com
-
We’ve teamed up with the Colorectal Cancer Alliance to help advance colorectal cancer research. The Genetic Insights into Colorectal Cancer in the Black Community study is part of 23andMe’s continued efforts to raise awareness about important health conditions that touch many individuals but disproportionately impact the Black and African American communities. Eligible participants will receive the 23andMe Health + Ancestry Service and compensation for their time and effort in helping us with this research. Learn more here: https://23and.me/4crks5x
-
-
Congratulations to our very own Maya Lowe for being featured in the San Francisco Business Times for "The Business of Pride" series! 🧬🌈 https://lnkd.in/gEUGiZuq
Corporate Pride: Maya Lowe exemplifies 23andMe's inclusive strategy - San Francisco Business Times
bizjournals.com
-
Research on Parkinson's disease by scientists at 23andMe, with support from The Michael J. Fox Foundation for Parkinson's Research, has uncovered new insights into the natural history of the LRRK2 G2019S variant. The findings, tracing back thousands of years, vividly illustrate how our DNA braids together history, ancestry, and health. Read more: https://23and.me/3X8IIVK #ParkinsonsDisease #Genetics
The Natural History of a Genetic Variant Associated with Parkinson's Disease
blog.23andme.com
-
This week, we released a new Bipolar Disorder PRS report*, adding to a collection of genetic reports focused on mental health that are available for 23andMe+ Premium members. Bipolar disorder affects millions of people worldwide, and according to the National Institute of Mental Health, an estimated 4.4 percent of American adults will experience bipolar disorder at some time in their lives. While research to fully understand the causes of bipolar disorder is ongoing, there are effective treatments, as well as strategies for managing the symptoms. Learn more: https://23and.me/3Xa71CB *The 23andMe Bipolar PRS report is based on a genetic model that includes data and insights from 23andMe consented research participants and incorporates thousands of genetic variants to provide information on the likelihood of developing bipolar disorder. The report does not describe a person’s overall likelihood, does not account for lifestyle or family history and has not been reviewed by the FDA. The Bipolar PRS report is not intended to tell you anything about your current state of health, or to be used to make medical decisions or determine any treatment.
-
-
Recapping an exciting week for 23andMe - our first ASCO! At the 2024 American Society of Clinical Oncology (ASCO) annual conference, we presented positive Phase 2 data from the Phase 1/2a clinical trial of 23ME-00610, our first wholly-owned antibody to enter the clinic. The 23andMe Therapeutics team presented the first data on monotherapy efficacy, including evidence of preliminary clinical benefit, and emerging biomarker data for 23ME-00610. Read more here: https://23and.me/4e8dnbK
-